PURPOSE: The candidate tumor suppressor ID4 is downregulated in various cancers by DNA hypermethylation. We have performed the first systematic analysis of ID4 expression and methylation in prostate cancer. METHODS: ID4 mRNA expression was analyzed by quantitative RT-PCR in 47 carcinoma and 13 benign prostatic tissues obtained by prostatectomy. Methylation was analyzed in an extended series of samples by methylation-specific MS-PCR and pyrosequencing, controlled by bisulfite sequencing. RESULTS: ID4 expression was significantly decreased in prostate cancers, especially in cases with adverse clinical and histopathological features and earlier recurrence. Hypermethylation in carcinomas was detected by MS-PCR and pyrosequencing, but the results of the two techniques were not fully concordant. The difference was created by generally partial and heterogeneous methylation. Weak methylation was also detected in benign prostatic tissue samples. CONCLUSIONS: ID4 downregulation may contribute to prostate cancer pathogenesis and is often accompanied by DNA hypermethylation. The case of ID4 illustrates exemplarily the limits and pitfalls of techniques for the detection of methylation changes in prostate cancer tissues.
PURPOSE: The candidate tumor suppressor ID4 is downregulated in various cancers by DNA hypermethylation. We have performed the first systematic analysis of ID4 expression and methylation in prostate cancer. METHODS:ID4 mRNA expression was analyzed by quantitative RT-PCR in 47 carcinoma and 13 benign prostatic tissues obtained by prostatectomy. Methylation was analyzed in an extended series of samples by methylation-specific MS-PCR and pyrosequencing, controlled by bisulfite sequencing. RESULTS:ID4 expression was significantly decreased in prostate cancers, especially in cases with adverse clinical and histopathological features and earlier recurrence. Hypermethylation in carcinomas was detected by MS-PCR and pyrosequencing, but the results of the two techniques were not fully concordant. The difference was created by generally partial and heterogeneous methylation. Weak methylation was also detected in benign prostatic tissue samples. CONCLUSIONS:ID4 downregulation may contribute to prostate cancer pathogenesis and is often accompanied by DNA hypermethylation. The case of ID4 illustrates exemplarily the limits and pitfalls of techniques for the detection of methylation changes in prostate cancer tissues.
Authors: Shih-Shih Chen; Rainer Claus; David M Lucas; Lianbo Yu; Jiang Qian; Amy S Ruppert; Derek A West; Katie E Williams; Amy J Johnson; Fred Sablitzky; Christoph Plass; John C Byrd Journal: Blood Date: 2010-11-22 Impact factor: 22.113
Authors: Isabel Steiner; Klaus Jung; Philipp Schatz; Torsten Horns; Daniel Wittschieber; Michael Lein; Manfred Dietel; Andreas Erbersdobler Journal: Pathobiology Date: 2010-11-29 Impact factor: 4.342
Authors: Naoyuki Umetani; Hiroya Takeuchi; Akihide Fujimoto; Masaru Shinozaki; Anton J Bilchik; Dave S B Hoon Journal: Clin Cancer Res Date: 2004-11-15 Impact factor: 12.531
Authors: Shannon R Payne; Jurgen Serth; Martin Schostak; Jorn Kamradt; Arne Strauss; Paul Thelen; Fabian Model; J Kevin Day; Volker Liebenberg; Andrew Morotti; Su Yamamura; Joe Lograsso; Andrew Sledziewski; Axel Semjonow Journal: Prostate Date: 2009-09-01 Impact factor: 4.104
Authors: Jean-Philippe Coppe; Yoko Itahana; Dan H Moore; James L Bennington; Pierre-Yves Desprez Journal: Clin Cancer Res Date: 2004-03-15 Impact factor: 12.531
Authors: Erik Noetzel; Jürgen Veeck; Dieter Niederacher; Oliver Galm; Felicitas Horn; Arndt Hartmann; Ruth Knüchel; Edgar Dahl Journal: BMC Cancer Date: 2008-05-30 Impact factor: 4.430